A potential biomarker of the association between hypothyroidism and reduced Meteorin-like levels: a case- control study
Main Article Content
Keywords
Hypothyroidism, subclinical hypothyroidism, overt hypothyroidism, Meteorin-like protein
Abstract
Background: Hypothyroidism occurs when the thyroid gland doesn't generate enough thyroid hormone. Meteorin like protein (Metrnl) a tiny secreted protein, regulates cell differentiation, survival, and migration in several organs.
Aim of study: The purpose of this research was to see whether serum Metrnl levels might be used as a biomarker for hypothyroidism complication.
Materials and Methods: This case-control study comprised 90 individuals ranging in age from 20 to 50 years. These people were separated into three groups: those with overt hypothyroidism (OH), those with subclinical hypothyroidism (SCH), and those who were healthy. sex, age, weight, height, body mass index (BMI), and hormonal indicators were all assessed and recorded for each participant.
Results: serum Metrnl levels were considerably lower in hypothyroid patients compared to those with normal thyroid function (p 0.001). Furthermore, Metrnl levels were negatively connected with TSH levels (r =- 0.32, p 0.041) and favorably correlated with T4 levels (r =0.303, p 0.040)..
Conclusion : Serum Metrnl levels may be a biomarker for hypothyroidism detection and monitoring. The research excluded systemic disorders and pharmaceutical usage to ensure accuracy. Thus serum Metrnl levels may be useful clinical tools for hypothyroidism identification and monitoring.
References
2. M. Li et al., “Elevated serum neuregulin 4 levels in patients with hyperthyroidism,” Endocr. Connect., vol. 8, no. 6, p. 728, 2019.
3. F. Xiao et al., “Elevated serum fibroblast growth factor 21 levels in patients with hyperthyroidism,” J. Clin. Endocrinol. Metab., vol. 100, no. 10, pp. 3800–3805, 2015.
4. M. Ruchala, A. Zybek, and E. Szczepanek-Parulska, “Serum irisin levels and thyroid function—Newly discovered association,” Peptides, vol. 60, pp. 51–55, 2014.
5. R. R. Rao et al., “Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis,” Cell, vol. 157, no. 6, pp. 1279–1291, 2014.
6. S. Zheng, Z. Li, J. Song, J. Liu, and C. Miao, “Metrnl: a secreted protein with new emerging functions,” Acta Pharmacol. Sin., vol. 37, no. 5, pp. 571–579, 2016.
7. T. W. Jung et al., “METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPARδ-dependent pathways in skeletal muscle of mice,” Exp. Mol. Med., vol. 50, no. 9, pp. 1–11, 2018.
8. H. N. Abd Ali and H. A. Ali, “The Effects of ANGPTL8 Levels and Correlated with Lipid Profiles and Insulin Resistance in Iraqi Patients with Overt and Subclinical Hypothyroidism,” Ann. Rom. Soc. Cell Biol., vol. 25, no. 6, pp. 169–181, 2021.
9. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, pp. 412–419, 1985.
10. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clin. Chem., vol. 18, no. 6, pp. 499–502, 1972.
11. G. S. Baht et al., “Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism,” Nat. Metab., vol. 2, no. 3, pp. 278–289, 2020, doi: 10.1038/s42255-020-0184-y.
12. Y. Du et al., “Inverse relationship between serum Metrnl levels and visceral fat obesity (VFO) in patients with type 2 diabetes,” Diabetes Res. Clin. Pract., vol. 161, p. 108068, 2020.
13. S. Pellitero et al., “Opposite changes in meteorin-like and oncostatin m levels are associated with metabolic improvements after bariatric surgery,” Int. J. Obes., vol. 42, no. 4, pp. 919–922, 2018.
14. J. Y. Bae, “Aerobic exercise increases meteorin-like protein in muscle and adipose tissue of chronic high-fat diet-induced obese mice,” Biomed Res. Int., vol. 2018, 2018.
15. L. Gong et al., “Decreased serum interleukin‐41/Metrnl levels in patients with Graves’
disease,” J. Clin. Lab. Anal., vol. 36, no. 10, p. e24676, 2022.
16. X. Ding et al., “Serum Metrnl levels are decreased in subjects with overweight or obesity and are independently associated with adverse lipid profile,” Front. Endocrinol. (Lausanne)., p. 2139, 2022.
17. J. H. Lee et al., “Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes,” Diabetes Res. Clin. Pract., vol. 135, pp. 7–10, 2018.
18. A. C. Bianco and E. A. McAninch, “The role of thyroid hormone and brown adipose tissue in energy homoeostasis,” lancet Diabetes Endocrinol., vol. 1, no. 3, pp. 250–258, 2013.
19. J. E. Silva and P. R. Larsen, “Potential of brown adipose tissue type II thyroxine 5’-deiodinase as a local and systemic source of triiodothyronine in rats.,” J. Clin. Invest., vol. 76, no. 6, pp. 2296–2305, 1985.
20. D. Salvatore, W. S. Simonides, M. Dentice, A. M. Zavacki, and P. R. Larsen, “Thyroid hormones and skeletal muscle—new insights and potential implications,” Nat. Rev. Endocrinol., vol. 10, no. 4, pp. 206–214, 2014.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.